Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

Stefano Luminari, Angela Ferrari, Martina Manni, Alessandra Dondi, Annalisa Chiarenza, Francesco Merli, Chiara Rusconi, Vittoria Tarantino, Alessandra Tucci, Umberto Vitolo, Sofia Kovalchuk, Emanuele Angelucci, Alessandro Pulsoni, Luca Arcaini, Francesco Angrilli, Gianluca Gaidano, Caterina Stelitano, Giovanni Bertoldero, Nicola Cascavilla, Flavia SalviAndrés J M Ferreri, Daniele Vallisa, Luigi Marcheselli, Massimo Federico

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.

Original languageEnglish
Pages (from-to)JCO2017741652
JournalJournal of Clinical Oncology
DOIs
Publication statusE-pub ahead of print - Nov 2 2017

Fingerprint

Mitoxantrone
Follicular Lymphoma
Vincristine
Prednisone
Cyclophosphamide
Therapeutics
Survival Rate
Treatment Failure
Disease-Free Survival
fludarabine
Rituximab
Lymphoma
Doxorubicin

Keywords

  • Journal Article

Cite this

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. / Luminari, Stefano; Ferrari, Angela; Manni, Martina; Dondi, Alessandra; Chiarenza, Annalisa; Merli, Francesco; Rusconi, Chiara; Tarantino, Vittoria; Tucci, Alessandra; Vitolo, Umberto; Kovalchuk, Sofia; Angelucci, Emanuele; Pulsoni, Alessandro; Arcaini, Luca; Angrilli, Francesco; Gaidano, Gianluca; Stelitano, Caterina; Bertoldero, Giovanni; Cascavilla, Nicola; Salvi, Flavia; Ferreri, Andrés J M; Vallisa, Daniele; Marcheselli, Luigi; Federico, Massimo.

In: Journal of Clinical Oncology, 02.11.2017, p. JCO2017741652.

Research output: Contribution to journalArticle

Luminari, S, Ferrari, A, Manni, M, Dondi, A, Chiarenza, A, Merli, F, Rusconi, C, Tarantino, V, Tucci, A, Vitolo, U, Kovalchuk, S, Angelucci, E, Pulsoni, A, Arcaini, L, Angrilli, F, Gaidano, G, Stelitano, C, Bertoldero, G, Cascavilla, N, Salvi, F, Ferreri, AJM, Vallisa, D, Marcheselli, L & Federico, M 2017, 'Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma', Journal of Clinical Oncology, pp. JCO2017741652. https://doi.org/10.1200/JCO.2017.74.1652
Luminari, Stefano ; Ferrari, Angela ; Manni, Martina ; Dondi, Alessandra ; Chiarenza, Annalisa ; Merli, Francesco ; Rusconi, Chiara ; Tarantino, Vittoria ; Tucci, Alessandra ; Vitolo, Umberto ; Kovalchuk, Sofia ; Angelucci, Emanuele ; Pulsoni, Alessandro ; Arcaini, Luca ; Angrilli, Francesco ; Gaidano, Gianluca ; Stelitano, Caterina ; Bertoldero, Giovanni ; Cascavilla, Nicola ; Salvi, Flavia ; Ferreri, Andrés J M ; Vallisa, Daniele ; Marcheselli, Luigi ; Federico, Massimo. / Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. In: Journal of Clinical Oncology. 2017 ; pp. JCO2017741652.
@article{885b83ab615541cd97439d025752efc5,
title = "Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma",
abstract = "Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44{\%} (95{\%} CI, 39{\%} to 49{\%}) and 48{\%} (95{\%} CI, 43{\%} to 53{\%}), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95{\%} CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95{\%} CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83{\%} (95{\%} CI, 79{\%} to 87{\%}), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83{\%} 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.",
keywords = "Journal Article",
author = "Stefano Luminari and Angela Ferrari and Martina Manni and Alessandra Dondi and Annalisa Chiarenza and Francesco Merli and Chiara Rusconi and Vittoria Tarantino and Alessandra Tucci and Umberto Vitolo and Sofia Kovalchuk and Emanuele Angelucci and Alessandro Pulsoni and Luca Arcaini and Francesco Angrilli and Gianluca Gaidano and Caterina Stelitano and Giovanni Bertoldero and Nicola Cascavilla and Flavia Salvi and Ferreri, {Andr{\'e}s J M} and Daniele Vallisa and Luigi Marcheselli and Massimo Federico",
year = "2017",
month = "11",
day = "2",
doi = "10.1200/JCO.2017.74.1652",
language = "English",
pages = "JCO2017741652",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

AU - Luminari, Stefano

AU - Ferrari, Angela

AU - Manni, Martina

AU - Dondi, Alessandra

AU - Chiarenza, Annalisa

AU - Merli, Francesco

AU - Rusconi, Chiara

AU - Tarantino, Vittoria

AU - Tucci, Alessandra

AU - Vitolo, Umberto

AU - Kovalchuk, Sofia

AU - Angelucci, Emanuele

AU - Pulsoni, Alessandro

AU - Arcaini, Luca

AU - Angrilli, Francesco

AU - Gaidano, Gianluca

AU - Stelitano, Caterina

AU - Bertoldero, Giovanni

AU - Cascavilla, Nicola

AU - Salvi, Flavia

AU - Ferreri, Andrés J M

AU - Vallisa, Daniele

AU - Marcheselli, Luigi

AU - Federico, Massimo

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.

AB - Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.

KW - Journal Article

U2 - 10.1200/JCO.2017.74.1652

DO - 10.1200/JCO.2017.74.1652

M3 - Article

C2 - 29095677

SP - JCO2017741652

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

ER -